Business
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
BOSTON, Nov. 6, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform
About this update from Metavia Inc.
[{"type":"text","content":"BOSTON, Nov. 6, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of James P. Tursi, M.D., a pharmaceutical industry veteran, to its Board of Directors, effective November 1, 2023. Dr. Tursi will also serve as a member of the Board's Nominating and Corporate Governance Committee.\n\n\"James is a proven leader, with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience,\" stated Andrew I. Koven, Chairman of NeuroBo's Board of Directors. \"Having served as both chief medical officer and chief scientific officer of a number of companies, over the years, James' expertise will be valuable as we continue to advance the clinical development of our two unique and promising cardiometabolic assets which address the large nonalcoholic steatohepatitis (NASH) and obesity markets. Specifically, we look forward to his counsel related to our development of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, currently in a Phase 2a clinical trial for the treatment NASH and, DA-1726, a novel oxyntomodulin (OXM) analogue that acts as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, for which we expect to file an Investigational New Drug (IND) application in the coming months, with the planned initiation of a Phase 1a safety study during the first half of 2024.\"\nDr. Tursi added, \"I am honored to join the NeuroBo Board of Directors during such a transformative stage for the Company, especially with multiple near-term milestones on the horizon, which could meaningfully drive shareholder value going forward. As such, I look forward to working closely with the NeuroBo leadership team and my fellow Directors to maximize the potential for the Company's next generation pharmaceuticals to treat cardiometabolic diseases.\"\nDr. Tursi is currently Executive Vice President – Global Research and Development for Endo International plc, which he joined in January 2022. Previously, from April 2020 until January 2022, Dr. Tursi was Chief Scientific Officer U.S. for Ferring Pharmaceuticals. From August 2018 until April 2020, Dr. Tursi served as Chief Medical Officer and Executive Vice President, Research and Development for Antares Pharma...